Skip to main content

Table 5 Results of base case analysis* as the difference between usual care and applying the AI tool

From: Cost-effectiveness of artificial intelligence aided vessel occlusion detection in acute stroke: an early health technology assessment

  Incremental costs ($) Incremental efficacy (QALYs)
Population Patient % of usual care Population Patient % of usual care
Acute phase (< 90 days) $4,295,152 $60 0.60 9.45 0.0001 0.06
Rest of life phase (> 90 days) − $15,510,277 − $216 − 0.36 672.82 0.0094 0.07
Total − $11,215,125 − $156 − 0.23 682.27 0.0095 0.07
  1. *Base case parameters: missed LVOs, 6%; costs per analysis, $40; reduction of missed LVOs, 50%
  2. QALY, quality-adjusted life-year
  3. Costs are rounded to the nearest integer